Osteopore secures landmark medical approval In China
Australian-Singaporean regenerative medicine pioneer Osteopore (ASX:OSX) secured a major regulatory breakthrough, obtaining approval from the Hainan Medical Products Administration.
The endorsement greenlights the clinical use and commercial sale of the company’s 3D-printed biomimetic and bioresorbable custom orthopaedic medical devices.
Initial operations will commence at the Hainan branch of the Shanghai Ruijin Hospital, situated within the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
As China’s sole special medical zone, Boao Lecheng operates under preferential national-level policies, enabling innovative, foreign-approved medical technologies to clear clinical hurdles and reach patients before receiving full, formal mainland approval.
The Hainan FDA licence functions as a vital strategic launchpad, offering Osteopore an accelerated commercial route and a regulatory springboard towards broader, nationwide market access.
Valued at US$2.5 billion in 2024, the domestic market is projected to climb to US$4.5 billion by 2035, progressing at a steady compound annual growth rate of 5.6%.
The company has already identified its first patient under the new scheme, with the inaugural surgery scheduled to take place in June.
At the time of reporting, Osteopore’s share price was $0.0080.
